Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses evaluating pembrolizumab vs placebo in stage IIB or IIC melanoma.
Georgina V. Long, BSc, PhD, MBBS
Advertisement
Articles by Georgina V. Long, BSc, PhD, MBBS
Georgina V. Long, BSc, PhD, MBBS, chair of Melanoma Medical Oncology and Translational Research at the Melanoma Institute of Australia (MIA) and Royal North Shore Hospital, University of Australia, discusses the patients with melanoma who respond best to the combination of dabrafenib plus trametinib.
Advertisement
Latest Updated Articles
Dr. Long on Treating Melanoma With Dabrafenib Plus TrametinibPublished: November 17th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5